NCT05473273 Descriptive Analysis of Serum Immunological Markers During an Euploid Frozen Embryo Transfer in a Natural Cycle.
| NCT ID | NCT05473273 |
| Status | Recruiting |
| Phase | — |
| Sponsor | ART Fertility Clinics LLC |
| Condition | Infertility, Female |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-04-24 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2023-04-24 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To describe the peripheral serum levels of the anti-inflammatory cytokines IL-4 (Interleukin-4), IL-10 (Interleukin-10), TGF-ß1 (Transforming Growth Factor beta1), the pro-inflammatory cytokines IL-17 (Interleukin-17), IFγ (Interferon Gamma) and the immune mediator PIBF (Progesterone-Induced Blocking Factor) along a single frozen euploid blastocyst transfer in a natural cycle (NC) or Hormone Replacement Therapy (HRT).
Eligibility Criteria
Inclusion Criteria: * Women aged 18 years to 40 years * Having at least one good quality (grade A or B for inner mass cell and trophectoderm) day 5 or 6 chromosomally normal cryopreserved blastocyst available for transfer * Single embryo transfer in a natural cycle (NC) or an Hormone Replacement Therapy (HRT) protocol * Fresh ejaculate used for fertilization Exclusion Criteria: * Body mass index lower than 18.5 or equal or higher than 29 kg/m2 * Endometriosis or adenomyosis suspected by medical history (dysmenorrhea, dyspareunia, heavy or prolonged menstrual bleeding (\> 8 days), chronic pelvic pain, catamenial rectal or bladder symptoms) or diagnosed by imaging (magnetic resonance imaging or ultrasonography) * Uterine abnormalities * Hydrosalpinx * Insulin resistance or diabetes mellitus diagnosed by HbA1c 5.7 % * Antiphospholipid syndrome * Polycystic ovarian syndrome according to Rotterdam criteria: presence of at least two of the following: irregular cycles (\< 21 or \> 35 days or \< 8 cycles a year), biochemical or clinical hyperandrogenism, ovarian ultrasound morphology (\> 20 follicles per ovary on transvaginal scan) or Anti-mullerian hormone \> 5,98 ng/ml * History of recurrent miscarriage, defined as the loss of 2 or more pregnancies according to ESHRE guidelines * History of implantation failure, considered as the lack of pregnancy after the transfer of 2 good-quality (grade A or B for inner mass cell and trophectoderm (29)) euploid embryos * History or suspicion of Asherman syndrome * Autoimmune disease * Couple first degree consanguineous
Contact & Investigator
LAURA MARQUETA MARQUES, Consultant
PRINCIPAL INVESTIGATOR
ART Fertility Clinics LLC
Frequently Asked Questions
Who can join the NCT05473273 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Infertility, Female. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05473273 currently recruiting?
Yes, NCT05473273 is actively recruiting participants. Contact the research team at barbara.lawrenz@artfertilityclinics.com for enrollment information.
Where is the NCT05473273 trial being conducted?
This trial is being conducted at Abu Dhabi, United Arab Emirates.
Who is sponsoring the NCT05473273 clinical trial?
NCT05473273 is sponsored by ART Fertility Clinics LLC. The principal investigator is LAURA MARQUETA MARQUES, Consultant at ART Fertility Clinics LLC. The trial plans to enroll 40 participants.